AC Immune
ACIU
45 hedge funds and large institutions have $73.9M invested in AC Immune in 2024 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 8 closing their positions.
1,957% more call options, than puts
Call options by funds: $144K | Put options by funds: $7K
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
5% more funds holding
Funds holding: 43 → 45 (+2)
0.83% less ownership
Funds ownership: 28.29% → 27.46% (-0.83%)
8% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 13
31% less capital invested
Capital invested by funds: $107M → $73.9M (-$32.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$1.26M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$476K |
| 3 |
Morgan Stanley
New York
|
+$317K |
| 4 |
Renaissance Technologies
New York
|
+$294K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$232K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$2.06M |
| 2 |
BlackRock
New York
|
-$1.44M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$846K |
| 4 |
EP
Eversept Partners
New York
|
-$375K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$351K |
ACIU Hedge Fund Activity: Q4 2024 in Review
45 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in AC Immune (ACIU) for Q4 2024, worth a combined $73.9M — down 31% from $107M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ACIU positions and 8 closed out — a net gain of 3 holders — while 12 added to existing stakes and 13 trimmed.
The largest buyer was Northern Trust, opening a new position worth an estimated $1.26M. The largest seller was Redmile Group, cutting an estimated $2.06M.
- 45 institutional investors held AC Immune (ACIU) as of Q4 2024, up from 43 in Q3 2024.
- Funds reported $73.9M of AC Immune stock for Q4 2024, down 31% quarter-over-quarter.
- 11 funds opened new AC Immune positions in Q4 2024 and 8 closed out, a net change of +3 holders.
- The largest AC Immune buyer in Q4 2024 was Northern Trust, an estimated $1.26M added.
- The largest AC Immune seller in Q4 2024 was Redmile Group, an estimated $2.06M sold.
Based on aggregated 13F filings for Q4 2024.